This study, a collaboration with Dr. Salazar’s lab at the University of Murcia in Spain, describes the beneficial effects of PRALICIGUAT and EMPAGLIFLOZIN on the pathophysiology associated with prolonged exposure of hypertensive rats with altered renal development (ARDev) to a high fat diet (HFD). Combined administration of PRALICIGUAT and EMPAGLIFLOZIN leads to a greater improvement of the cardiovascular (including arterial pressure), renal (including renal vascular resistance), and metabolic dysfunction (including glucose tolerance, body weight gain, and insulin resistance index) in these ARDev rats on HFD than the treatment with either PRALICIGUAT or EMPAGLIFLOZIN alone.